Multicancer Early Detection (MCED) Consortium

📢 The AHRQ has released a protocol for Blood-Based Tests for Multiple Cancer Screening! 🩸 The Evidence-based Practice Center (EPC) Program at the Agency for Healthcare Research and Quality (AHRQ) has posted this important protocol, which is available on the Effective Healthcare website. 🔍 If you have unpublished scientific information related to this topic, they encourage you to submit it via the Supplemental Evidence and Data for Systematic Reviews (SEADS) portal by August 22, 2024. Please note that materials submitted may be made public. This review aims to assess the accuracy, effectiveness, and potential harms of using blood-based biomarkers for multiple cancer screening. The protocol outlines the purpose, scope, key questions, and criteria for including studies in the review. The protocol is available at the Effective Healthcare Web site: https://lnkd.in/eCcjZssm Submit your information here: https://lnkd.in/edtJ3W-B

Exciting News! Enrollment has begun in the Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare) study sponsored by GRAIL! 🌟Community Health Network has begun enrollment in this prospective, multi-center study to assess the clinical impact of the Galleri multi-cancer early detection (MCED) test in Medicare beneficiaries. This study focuses on including historically underrepresented communities, including seniors, diverse racial and ethnic groups, socioeconomically disadvantaged, and rural populations. 🌟 Over the next three years, up to 50,000 Medicare beneficiaries across 50 study sites will either receive usual care plus an annual Galleri test or usual care without the test. The study will assess the reduction in diagnosed stage IV cancers, safety, and healthcare resource utilization. 🌟 Conducted under an FDA-approved Investigational Device Exemption (IDE) and approved by Centers for Medicare & Medicaid Services, Medicare will cover the Galleri test and related costs for study participants. Stay tuned for updates on our website! https://www.mced.info

Day 2 of the MCED Annual Summit has been incredibly valuable, sparking new topics and insights to consider for our work. 🌟 Morning Panel Discussion: MCED Implementation & Health Disparities The panel explored successes and challenges from the perspective of a large medical system and key considerations regarding health disparities, access, and outreach to minority communities. Co-hosted by: Richard Wender, MD Chair and Professor, Dept. of Family Medicine and Community Health, Perelman School of Medicine, Univ. of Pennsylvania Esther Krofah: Executive Director, FasterCures and Center for Public Health, Milken Institute Panelists: Jonathon Rendina, PhD, MPH: Senior Director of Research, Whitman-Walker Institute Damon Broyles, MD, FAAFP: VP, Clinical Innovation, Mercy Technology Services; Medical Director, Multi-Cancer Early Detection, Mercy Precision Medicine Ian Jasenof, MD, FACOG, MHA, CPE: Chief Medical Officer, Mile Square Health Center 🌟 Discussion on Patient Navigation: The conversation then shifted to patient navigation, enriched by diverse perspectives from both community and health system navigators. Moderated by the experienced Dr. Carmen Guerra, who welcomed Ian Lowenhoff, Trial Manager, NHS-Galleri Trial, Cancer Research UK Cancer Prevention Trials Unit, Queen Mary’s University London, to share his insights on integrating patient navigation in the NHS-Galleri trials. 🌟 Workgroup Report Outs: The day concluded with workgroup report-outs summarizing the rich discussions from Day 1 and outlining their accomplishments and future goals. The time spent together has been fruitful, and we are excited about the work ahead! As always, visit our website for updates! https://www.mced.info/

🚀 Today marks Day 1 of our Annual Summit for our members! This morning, we were thrilled to welcome special guest Professor Anne Mackie, Director of Screening from Public Health England, who shared her insights on the UK's approach to MCEDs. Special thanks to Robert Smith, Vice President of Early Cancer Detection Science at the American Cancer Society, for his valuable contributions. We engaged in an important conversation about the critical issues facing the field! We also heard from Lauren C. Leiman, Executive Director of BLOODPAC, and Christina Clarke Dur, PhD, MPH, Vice President of Epidemiology and Distinguished Scientist at GRAIL. They discussed BLOODPAC's work in blood-based screening for early cancer detection, including a lexicon project to standardize terminology in the liquid biopsy and early cancer detection technology space and their in-depth exploration of how we should rethink risk and risk assessment for liquid biopsy-based single- and multi-cancer screening. This afternoon, our workgroups dove into productive sessions to map out our next steps. These sessions focused on developing actionable plans and strategies to advance our initiatives in early cancer detection and improving healthcare outcomes. Stay tuned for updates! https://mced.info #Summit2024 #HealthInnovation #Collaboration

🎉 Congratulations to GRAIL for achieving a major milestone by enrolling over 35,000 participants in the PATHFINDER 2 Study! This diverse group represents various socio-economic, ethnic, gender, and age backgrounds. Results from the first 25,000 participants are expected in the second half of 2025! They have also completed the final study visits for the NHS-Galleri Trial. Final results are anticipated in 2026. 📅

📣 Exciting News from our member Exact Sciences!

ICYMI: A new article from Cancer Research UK (CRUK) delves into the current landscape of Multicancer Tests (MCT) that include Multi-Cancer Early Detection (MCED) tests. While we're still in the early stages, recent advancements show promising results that could lead to earlier and more accurate cancer detection, ultimately saving more lives. Stay informed about the future of cancer diagnostics! Read the full article here: https://lnkd.in/eNd6zYjA #CancerResearch #EarlyDetection #MCED #HealthInnovation #CancerAwareness

🚀 Join Us in the Fight Against Cancer and for Equitable Inclusion in Clinical Trials! Project Community at the FDA Oncology Center of Excellence launched the National Black Family Cancer Awareness initiative in 2021, marking the 50th anniversary of the National Cancer Act and the signing of Presidential Executive Order 13985. Originally a week-long social media campaign, this initiative has now grown into a year-round project dedicated to increasing cancer awareness among one of the most vulnerable segments of the US population. The mission is to engage community-based stakeholders, enhance knowledge about cancer clinical trial participation, and encourage minority population specimen donations to national genomic databases for cancer research. Learn more about this initiative https://lnkd.in/eyBfVGvX 🌟 Let's work together to make a difference. Share this post and help us spread the word! #BlackFamCan

ASCO Conference Update At the ASCO conference this week, a session titled "MCED: Tests May Have a Role in Health Equity, but We’re Not There Yet" drew a packed house to discuss the current state of the technology. AJMC - The American Journal of Managed Care covered the session, highlighting discussions on the state of MCEDs, their potential to build equity, efforts to ensure payment, and considerations of risk and overdiagnosis. Coalition Member Robert A. Smith, PhD, senior vice president of the American Cancer Society, was a panelist. Read the article to learn more about the future of multicancer early detection and its implications for healthcare equity. https://lnkd.in/eTgw8pwg #CancerDetection #HealthEquity #MCED

🚨 Update: NHS-Galleri Trial 🚨 NHS England has reviewed the first year of the NHS-Galleri trial and has decided to await the final results, expected in 2026, before considering a nationwide rollout of the Galleri multi-cancer early detection test (MCBT). Stay tuned for more updates! Read the NHS blog https://lnkd.in/eV2hmQ6V